

1 **Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in the UK vaccination**
2 **programme, during the Spring-Summer (monovalent vaccine) and Autumn-Winter 2022**
3 **(bivalent vaccine) booster campaigns: a prospective test negative case-control study**

4 Dr Anastasia Chatzilela PhD[†], Engineering Mathematics, University of Bristol, Bristol, UK

5 Dr Catherine Hyams PhD[†], Population Health Sciences, University of Bristol, Bristol, UK

6 Dr Rob Challen PhD, Engineering Mathematics, University of Bristol, Bristol, UK

7 Dr Robin Marlow PhD, Population Health Sciences, University of Bristol, Bristol, UK

8 Ms Jade King MSc, Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK

9 Mr David Adegbite BSc, Bristol Vaccine Centre, Population Health Sciences, University of
10 Bristol, Bristol, UK

11 Ms Jane Kinney BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol,
12 Bristol, UK

13 Ms Madeleine Clout BSc, Bristol Vaccine Centre, Population Health Sciences, University of
14 Bristol, Bristol, UK

15 Prof Nick Maskell MD, Academic Respiratory Unit, University of Bristol, Southmead Hospital,
16 Bristol, UK

17 Dr Jennifer Oliver PhD, Bristol Vaccine Centre, Population Health Sciences, University of
18 Bristol, Bristol, UK

19 Professor Adam Finn PhD[†], Bristol Vaccine Centre, Cellular and Molecular Medicine and
20 Population Health Sciences, University of Bristol, Bristol, UK

21 Dr Leon Danon PhD[†], Engineering Mathematics, University of Bristol, Bristol, UK
22 (Corresponding Author)

23 The Avon CAP Research Group

24 [†] These authors contributed equally, and should be considered co-first or last authors

25

26 Corresponding Author: Leon Danon, PhD

27 Engineering Mathematics, University of Bristol

28 University Walk
29 Bristol BS8 1TW
30 United Kingdom
31 +44(0)117 455 7828
32 l.danon@bristol.ac.uk

33

34 Keywords: COVID-19, SARS-CoV-2, respiratory infection, vaccination

35 **ABSTRACT (241/250 words)**

36 **Background**

37 Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations
38 against SARS-CoV-2 infection is an urgent public health priority. A precise comparison of the
39 rVE of monovalent and bivalent boosters given during the 2022 Spring-Summer and Autumn-
40 Winter campaigns, respectively, in a defined population has not been reported. We therefore
41 assessed rVE against hospitalisation for the Spring-Summer (fourth vs third monovalent mRNA
42 vaccine doses) and Autumn-Winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA
43 vaccine dose) boosters.

44 **Methods**

45 A prospective single-centre test-negative design case-control study of ≥ 75 year-olds hospitalised
46 with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling
47 for age, gender, socioeconomic status, patient comorbidities, community SARS-CoV-2
48 prevalence, vaccine brand and time between baseline dose and hospitalisation.

49 **Results**

50 682 controls and 182 cases were included in the Spring-Summer booster analysis; 572 controls
51 and 152 cases for the Autumn-Winter booster analysis. A monovalent mRNA COVID-19
52 vaccine as fourth dose showed rVE 46.9% (95% confidence interval [CI] 14.4-67.3) versus those
53 not boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had rVE 46.4% (95%CI 17.5-
54 65), compared to a fourth monovalent mRNA COVID-19 vaccine dose.

55 **Interpretation**

56 Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses
57 demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offer equivalent
58 protection against hospitalisation with Omicron infection to monovalent mRNA boosters given
59 earlier in the year. These findings support the current UK immunisation programme that advises
60 the use of bivalent booster doses.

61 INTRODUCTION

62 Following the emergence of wild-type SARS-CoV-2 and circulation of antigenically distinct
63 variants, large-scale vaccination programmes were implemented to reduce overall COVID-19
64 morbidity and mortality. In the UK, several COVID-19 vaccines received rapid regulatory
65 authorisation: the vaccines used initially were the monovalent mRNA vaccine BNT162b2
66 (Cominarty®) and the ChAdOx1 (Vaxzevria®) replication-deficient simian adenovirus vector
67 vaccine, with mRNA-1273 (Spikevax®) vaccine incorporated a few months later. These three
68 COVID-19 vaccines were used in the primary campaign, with the mRNA vaccines offered as
69 boosters from September 2021 for older people, extending to all adults in November 2021. A
70 fourth dose of an mRNA vaccine was offered from March 2022 and prioritised the most
71 vulnerable: all adults aged ≥ 75 years (y), and those in clinical risk groups[1]. A third priming
72 vaccine dose had already been offered to immunosuppressed individuals, so that for them, the
73 autumn 2021 and spring 2022 boosters were generally their fourth and fifth doses, respectively.
74 The COV-Boost study indicated that a fourth-dose COVID-19 mRNA vaccination boosts
75 immune responses[2], and observational studies showed three or four-dose vaccine effectiveness
76 (VE) against hospitalisation of 60.9-62.1% against BA.4 or BA.5 and 50.1% against BA.2 when
77 compared to two-doses received ≥ 25 weeks earlier[3]. These initial COVID-19 vaccines were
78 developed against wild-type virus and provided significant protection against infection,
79 hospitalisation, severe disease and death[4–8]. However, VE has been eroded progressively both
80 by waning of immune-protection over time and emergence of SARS-CoV-2 variants of concern
81 (VOC) (Alpha, Delta, Omicron) which show immune escape[9–12].

82

83 In summer 2022, the UK MHRA approved two new bivalent booster vaccines which were
84 developed in response to concerns about such viral evolution and escape. The Moderna bivalent
85 vaccine (Spikevax® bivalent Original/Omicron) was approved on 15th August 2022, followed
86 quickly by Pfizer/BioNTech bivalent vaccine (Comirnaty® Original/Omicron BA.1) approval on
87 3rd September 2022[13,14]. The Moderna vaccine contains 25mcg of mRNA coding for the
88 spike protein of the ancestral strain and 25mcg of mRNA against Omicron (BA.1) and the Pfizer
89 BioNTech vaccine contains 15mcg of mRNA directed against the ancestral strain and 15mcg of
90 mRNA against Omicron (BA.1). Early immunogenicity studies suggest bivalent mRNA boosters
91 induce similar or higher neutralising antibody levels against Omicron sub-variants and other
92 VOCs compared to monovalent mRNA boosters[15–19].

93

94 SARS-CoV-2 infection incidence remains high[20], whilst determining whether patients who
95 test SARS-CoV-2 positive have COVID-19 has become increasingly challenging. Additionally,
96 comparison between vaccinated individuals and those who have not received any COVID-19
97 vaccine dose cannot be performed, as almost the whole population is vaccinated or had prior
98 exposure to SARS-CoV-2: thus even unvaccinated individuals have some immunity to SARS-
99 CoV-2. There remains an absence of evidence of bivalent vaccines' clinical effectiveness when
100 compared to monovalent formulations because the different vaccine rollout timings make a direct
101 comparison of the vaccines impossible. Acknowledging this constraint, we undertook a test-
102 negative design (TND) case control study comparing SARS-CoV-2 positive and negative acute
103 lower respiratory tract disease (aLRTD) patients, assessing the protection against SARS-CoV-2
104 hospitalisation provided by an additional monovalent or bivalent mRNA vaccine dose compared

105 to those who had not received the respective doses, focusing on ≥ 75 y olds who were the main
106 target group in the spring 2022 booster programme.

107 **METHODS**

108 **Study design and conduct**

109 We estimated the relative vaccine effectiveness (rVE) of monovalent and bivalent mRNA
110 vaccines against hospitalisation in Bristol, within the study population consisting of adults
111 admitted to North Bristol and University Hospitals Bristol and Weston NHS Trusts [AvonCAP:
112 ISRCTN17354061] between 4th April 2022 and 30th July 2022 (the period following the
113 initiation of distribution of fourth dose of monovalent mRNA vaccines), and between 21st
114 September 2022 and 23rd January 2023 (the period following the initiation of distribution of
115 bivalent mRNA vaccines) inclusive. During the study period BA.4, BA.2 and BA.5 were the
116 main Omicron sub-lineages identified in COVID-19 cases in Bristol[21]. The study population
117 consisted of patients with signs/symptoms of respiratory infection, aged ≥ 18 y at the time of
118 hospitalisation[22]. Study eligible cases and controls eligible were identified from the medical
119 admission list, and data were collected from medical records using REDCap software[23]. All
120 data collection was undertaken by individuals not involved in analysis and blinded to results,
121 following the same procedures for both cases and controls. Vaccination records for every study
122 participant were obtained from linked hospital and GP records, including vaccine brand and date
123 of administration with data collection performed by individuals blinded to participants' SARS-
124 CoV-2 test results[24].

125

126

127

128 **Case definition and exclusions**

129 We included patients with ≥ 2 signs of acute respiratory disease or a confirmed
130 clinical/radiological diagnosis of aLRTD[24]. Patients hospitalised with aLRTD and positive
131 admission SARS-CoV-2 test using the UKHSA diagnostic assay in use at the time were
132 classified as cases; those with aLRTD and negative SARS-CoV-2 result were classified as
133 controls. Eligible controls could have multiple hospitalisations, provided subsequent admissions
134 were >7 days following previous discharge. We included only the first COVID-19 admission for
135 each case.

136

137 We excluded patients whose admission date was >10 days after symptom onset date (to avoid
138 including potentially false negative admission SARS-CoV-2 tests), and those with a confirmed
139 previous SARS-CoV-2 infection. Patients who had received 2 vaccine doses or fewer at the time
140 of admission were also excluded (Supplementary Data S1).

141

142 **Exposure definition**

143 This analysis aims to measure the protection offered by an additional dose of monovalent
144 (Original ‘wild-type’ mRNA vaccine, Pfizer-BioNTech [Comirnaty®] or Moderna [Spikevax®])
145 and bivalent (Original ‘wild-type’/Omicron BA.1 mRNA vaccine, Pfizer-BioNTech
146 [Comirnaty®] or Moderna [Spikevax®]) vaccine, each compared with those who had not
147 received the respective boosters, side by side, during SARS-CoV-2 Omicron variant dominance.
148 The Spring-Summer monovalent booster analysis (admissions 04/04/22-30/07/22) compares the

149 fourth dose of monovalent given as a booster(21/03/22-07/08/22) in the UK, to the third dose of
150 monovalent vaccine during Autumn-Winter 2021 (16/09/21-14/02/22). The Autumn-Winter
151 bivalent booster analysis (admissions 21/09/22-23/01/23) compares the fifth dose of vaccine,
152 with the bivalent formulation given as a booster (07/09/22-12/02/23) to the fourth dose of
153 monovalent vaccine in Spring-Summer 2022 (21/03/22-07/08/22).

154

155 For the Spring-Summer monovalent booster analysis, individuals were defined as boosted with a
156 monovalent vaccine if they had received three doses of any monovalent vaccine combination and
157 a fourth dose of monovalent vaccine during the Spring-Summer 2022 vaccination programme,
158 and no more than three months prior to their admission, and as unboosted only if they had
159 received two doses of any vaccine combination followed by a third dose of monovalent vaccine
160 during Autumn-Winter 2021. For the Autumn-Winter bivalent booster analysis, individuals were
161 defined as boosted with a bivalent vaccine if they had received four doses of any vaccine
162 combination plus a fifth bivalent dose during Spring-Summer 2022 vaccination programme and
163 no more than three months prior to their admission, and as unboosted if they had received three
164 doses of any vaccine combination plus a fourth monovalent dose during Autumn-Winter 2022. In
165 both analyses, we define those having received the most recent dose with >7 days having elapsed
166 between the vaccine and symptom onset as immunised (Supplementary Data S1).

167

168 The Joint Committee on Vaccination and Immunisation (JCVI) advised targeting COVID-19
169 booster vaccines during spring-summer towards those at highest risk of severe disease; those
170 aged ≥ 75 y and residents in long-term care facilities (LTCFs)[1], while in Autumn-Winter 2022

171 the offer was extended, including those aged ≥ 50 y and frontline health and social care
172 workers[25]. To make a comparison of the effectiveness of the different booster vaccine
173 formulations, we restricted both analyses to individuals aged ≥ 75 y.

174

175 Individuals who received a third vaccine dose in Autumn-Winter 2021, a fourth dose in Spring-
176 Summer 2022 and a fifth dose in Autumn-Winter 2022, are those who had received two doses as
177 the primary vaccination regimen before and during Spring-Summer 2021. However, individuals
178 with severe immunosuppression around the time of their first or second vaccine doses were
179 offered an additional primary dose (third dose) before any booster doses. As a result, they were
180 offered a fourth vaccine dose in Autumn-Winter 2021, a fifth dose in Spring-Summer 2022 and a
181 sixth dose in Autumn-Winter 2022 (Figure 1, Supplementary Data S2). As additional sensitivity
182 analyses, we included individuals who had received three doses as their primary vaccination
183 regimen in both comparisons.

184

185 **Outcomes**

186 We assessed the additional protection provided by a fourth dose of mRNA monovalent vaccine
187 and a fifth dose of bivalent vaccine as boosters against the primary endpoint of hospital
188 admission with either a clinical or radiological aLRTD diagnosis or aLRTD signs/symptoms
189 compared to that provided by three or four doses of the monovalent formulations of the vaccines,
190 respectively.

191

192 **Statistical Analysis**

193 Demographic, clinical characteristics and other factors that may affect the exposure (vaccination
194 status) or outcome (hospital admission) were compared between cases and controls for both
195 comparisons, between monovalent vaccine boosted and not boosted, and between boosted with a
196 bivalent vaccine and not boosted, using Fisher exact tests (categorical variables), two-sided
197 Kolmogorov-Smirnov tests (continuous variables) and Wilcoxon rank-sum tests (score
198 variables).

199

200 Under TND assumptions, we estimate the odds ratio of testing SARS-CoV-2 positive among
201 patients boosted with a monovalent vaccine versus those not boosted (rOR) and define rVE as
202 $(1-rOR) \times 100$. Similarly, we estimated rVE of bivalent booster, comparing the odds of testing
203 positive for SARS-CoV-2 among patients boosted with a bivalent vaccine versus those not
204 boosted. This was done using univariable logistic regression (Univariable Logistic Regression
205 Model). Differences in the timing of third/fourth/fifth dose and rollout timings of different
206 vaccine brands could introduce unobserved biases, confounding results in both comparisons. To
207 mitigate these, we performed multivariable logistic regression analyses adjusting for time
208 between baseline vaccine dose and admission (in days), vaccine brand [binary variable], age,
209 gender, Index of Multiple Deprivations (IMD) decile rank and Charlson comorbidity index (CCI)
210 [continuous variable], LTCF residency status, presence of pre-existing respiratory disease, and
211 community SARS-CoV-2 prevalence lagged by time interval between infection and
212 hospitalisation, assumed to be 8-days (Multivariable Logistic Regression Model).

213

214 We also conducted sensitivity analyses, matching cases and controls using propensity score
215 balancing using logistic regression to define propensity score, and nearest neighbour matching.
216 Matching variables included age, gender, CCI and IMD, LTCF residency status and presence of
217 pre-existing respiratory disease, and likelihood of vaccine receipt (Matched Conditional Logistic
218 Regression Model). Matching by elapsed time since baseline vaccine dose/brand was not
219 performed to avoid introducing bias[26]. Time since baseline vaccine dose/ brand is affected by
220 dose of last vaccine received; each booster was deployed ≥ 4 months after the previous COVID-
221 19 booster programme (Figure 1), with different programmes using different proportions of each
222 vaccine brand. As additional sensitivity analysis, we included individuals who had received three
223 doses as primary vaccination regimen, adjusting for the number of primary doses [binary
224 variable], using the same methods for both comparisons.

225

226 Statistical analyses were performed with R v4.0.2. Missing data were limited to the IMD variable
227 and accounted for <1%; no imputation was performed; all analyses only included participants
228 with complete data. Statistical significance was defined using a 2-sided significance level of
229 $\alpha=0.05$.

230

231 **Ethics and permissions**

232 The Health Research Authority Research Ethics Committee (East of England, Essex),
233 REC20/EE/0157 approved this study, including using Section 251 of the 2006 NHS Act under
234 Confidentiality Advisory Group authorisation.

235

236 **Role of the funding source**

237 This study was conducted as a collaboration between The University of Bristol (study sponsor)
238 and Pfizer (study funder). The study funder did not undertake any data collection, data analysis
239 or manuscript preparation.

240 RESULTS

241 During the periods evaluated, 9,868 adult aLRTD hospitalisations occurred in Bristol, UK, while
242 the Omicron variant was dominant[21,27,28]. In the Spring-Summer booster, 864 admissions of
243 ≥ 75 y old patients hospitalised with SARS-CoV-2 aLRTD were eligible for this analysis: median
244 patient age was 85y (IQR 79-90), 96 individuals (53%) were male, median CCI was 5 (IQR 4-6)
245 with no significant differences in patient age, gender, demographics, and health status compared
246 to patients hospitalised with SARS-CoV-2 negative aLRTD (Figure 1, Table 1, Supplementary
247 Data S3). In the Autumn-Winter booster, 884 admissions were eligible with no significant
248 differences in gender, demographics, and health status of study eligible patients admitted with
249 SARS-CoV-2 aLRTD compared to ≥ 75 y old patients hospitalised with SARS-CoV-2 negative
250 aLRTD (Figure 1, Table 2, Supplementary Data S4).

251

252 In the Spring-Summer booster analysis, of the 182 SARS-CoV-2 cases, 78 (43%) received a
253 fourth monovalent vaccine dose and 104 (57%) received a third monovalent vaccine dose, while
254 413 of 682 controls (61%) received a fourth monovalent vaccine dose and 269 (39%) received a
255 third monovalent vaccine dose, giving an unadjusted rVE of 51.2% (95%CI 32.1-65). The results
256 from the adjusted logistic regression model indicated that the additional protection against
257 hospitalisation was 46.9% (95%CI 14.4-67.3) when boosted with a fourth monovalent vaccine
258 dose compared to those who received only a third monovalent vaccine dose (Table 3). Matched
259 conditional logistic regression rVE was 52.4% (95%CI 21.4-71.2). Sensitivity analysis including
260 individuals with three doses as primary vaccination regimen resulted in lower rVE estimates
261 compared with results from the main analysis (Table 3, Supplementary Data S5, S6, S9).

262

263 In the Autumn-Winter booster analysis, of the 152 SARS-CoV-2 cases, 100 (66%) received a
264 fifth BA.1/ancestral bivalent vaccine dose and 52 (34%) received a fourth monovalent vaccine
265 dose, while 572 of 732 (78%) controls received a fifth bivalent vaccine dose and 160 (22%)
266 received a fourth monovalent vaccine dose, giving an unadjusted rVE of 46.2% (95%CI 21.1-
267 63). According to the adjusted logistic regression model, the adjusted rVE of a fifth bivalent
268 vaccine dose as a booster compared to a fourth monovalent vaccine dose was 46.4% (95%CI
269 17.5-65). Matched conditional logistic regression rVE was 48.5% (95%CI 19.3-67.1) (Table 4).
270 The inclusion of individuals with three doses as primary vaccination regimen produced estimates
271 comparable with results from the main analysis (Table 4, Supplementary Data S7, S8, S10).

272 DISCUSSION

273 In this analysis, we consider the public health implications of monovalent and bivalent vaccine
274 implementation, focussing on people aged ≥ 75 y; a high-risk group which was a primary target
275 for the UK vaccination programme. Although COVID-19 vaccines have been shown to be
276 effective against severe COVID-19 disease[4,29,30], it has not been possible to compare the
277 effectiveness of monovalent boosters directly with BA.1/ancestral bivalent booster doses of
278 mRNA COVID-19 vaccines in defined populations, because bivalent formulations rapidly and
279 entirely replaced monovalent formulations in the most recent booster programmes. In this
280 prospective study, we undertake a sequential analysis of the two vaccines given as boosters
281 during two booster programmes in the same calendar year, providing evidence that monovalent
282 vaccine (Original ‘wild-type’ Comirnaty® and Spikevax®) and BA.1/ancestral mRNA bivalent
283 vaccine (Original ‘wild-type’/Omicron BA.1 Cominarty® and SpikeVax®) provided similar
284 additional protection over and above that afforded by previous doses without the respective
285 boosters against hospitalisation from Omicron SARS-CoV-2 sub-variants in older individuals.

286

287 Specifically, we estimated that receiving a fourth monovalent mRNA vaccine dose within three
288 months was associated with a 46.9% (95%CI 14.4-67.3) relative reduction in hospitalisation risk
289 compared to three doses, in individuals ≥ 75 y, during Omicron BA.2/BA.4/BA.5 lineage
290 dominance. A fifth bivalent mRNA vaccine dose given within three months is estimated to
291 provide 46.4% (95%CI 17.5-65) additional protection against hospitalisation compared to four
292 doses, in the same ≥ 75 y age group, during a period in which alongside Omicron
293 BA.2/BA.4/BA.5 related sublineages, the XBB recombinant lineage and its mutation XBB.1.5

294 emerged [27]. Although our results demonstrate that both vaccine formulations combined in
295 these booster programmes had benefits when used as boosters, we have insufficient case
296 numbers to draw conclusions about individual vaccine brands or directly compare them.
297 Importantly, this analysis is restricted to individuals ≥ 75 y old, with 97-98% of unboosted
298 individuals in our sample having received their last dose more than 3 months prior to admission
299 (Supplementary Data S2), and provides encouraging evidence of similar benefit of monovalent
300 and bivalent boosters in older adults. Older adults are at increased risk of severe disease, and
301 protection may wane faster[31]; older adults were therefore targeted in the UK Spring-Summer
302 2022 and Autumn-Winter 2022 COVID-19 booster programmes. Regarding individuals with
303 severely weakened immune systems who were eligible for three primary doses, our analysis
304 based on their inclusion in our basic comparisons, suggests that both vaccine formulations may
305 offer some additional protection.

306

307 Vaccination against SARS-CoV-2 is independently associated with lower COVID-19
308 severity[4,29,30], and vaccines have been an important disease modifier during the pandemic.
309 Our estimates suggest that the bivalent boosters provided equivalent protection as monovalent
310 boosters in a real-world setting: results concordant with early evidence suggesting neutralising
311 antibody titres induced against Omicron by a bivalent booster dose were not higher than
312 following a monovalent booster dose in small studies[16,17]. Our results are concordant with a
313 recent UKHSA analysis[32] which estimated the incremental protection conferred by a fourth
314 monovalent dose compared to waned third dose was 58.8% (95%CI 54-63%), while the
315 additional protection of BA.1/ancestral mRNA bivalent vaccines relative to those with ≥ 2 doses
316 and waned protection was 57% (95%CI 48-65%), during the same time period as our analysis.

317

318 Since the study took place over the course of two different time periods, the interpretation of this
319 sequential comparison of the two vaccine formulations has to take into account the different
320 variants circulating[21,27,28]. Currently, there is no evidence that Omicron BA.2-related
321 sublineages, Omicron BA.5-related sublineages and XBB recombinant-related sublineages,
322 which appeared during the study period of the BA.1/ancestral mRNA bivalent boosters, cause
323 more severe disease. The impact of these lineages on the effectiveness of the BA.1/ancestral
324 mRNA bivalent formulation has not yet been studied in detail.

325

326 The TND has been described previously, along with its advantages and limitations[12,24,33],
327 and our analysis has some important additional strengths and limitations. The strength of our
328 approach is the focus on using real-world data, while accounting for the potential effects of
329 vaccine waning, and comorbidities. By limiting our analysis to boosted individuals only, our
330 analysis sidesteps the potentially unfair comparisons between populations that have followed UK
331 COVID-19 vaccine recommendations and unvaccinated populations that may display other
332 idiosyncratic behaviours. We also utilised symptom onset date to define illness start time and are
333 able to confirm that there is no difference in time since vaccination between the case and control
334 groups compared. We, therefore, define illness onset relative to both vaccination and
335 hospitalisation date accurately, without relying on positive test date (which may vary widely),
336 eliminating this source of bias or misclassification. All patients were hospitalised with acute
337 respiratory illness, so these results are unlikely to be subject to significant bias caused by
338 admission for other causes (i.e., incidental COVID-19 disease). Most notably, our estimates for

339 the effect of individual vaccines are underpowered, due to small patient numbers in our cohort
340 during the phases of the UK vaccination programme and study periods. We are unable to assess
341 additional protection against other markers of disease severity, such as admission to intensive
342 care or requirement for respiratory support, due to the small number of eligible admissions in this
343 time period. This analysis does not measure rVE in individuals who were not hospitalised or
344 were asymptomatic, so we cannot determine protection against asymptomatic disease or
345 transmission. Treatment biases may result in community-based treatment, death before
346 admission, or patients may otherwise not be referred to hospital. We note that this cohort, whilst
347 broadly representative of the UK population, was predominantly Caucasian and the studied
348 vaccines may have different effectiveness in individuals from other ethnic backgrounds.

349

350 In this prospective study, we provide evidence that autumn BA.1/ancestral mRNA bivalent
351 COVID-19 boosters offered equivalent augmentation of protection against Omicron
352 hospitalisation to that induced by spring monovalent mRNA boosters in 2022. Our findings
353 support the current UK immunisation programme, that advises the use of bivalent booster doses
354 in high-risk individuals.

355 **FIGURE LEGENDS**

356

357 **Figure One: Study Flow Diagram**

358 (A) Inclusion and exclusion criteria in the cohort. Of the 55 SARS-CoV-2 positive individuals,
359 33 were vaccinated with 5/6th dose bivalent mRNA vaccine, and 22 were vaccinated with 5/6th
360 dose monovalent mRNA vaccine. Of the 350 SARS-CoV-2 negative individuals admitted, 269
361 were vaccinated with 5/6th dose bivalent mRNA vaccine and 81 were vaccinated with 5/6th dose
362 monovalent mRNA vaccine. (B) Study timeline

363 **Data Sharing**

364 The data used in this study are sensitive and cannot be made publicly available without
365 breaching patient confidentiality rules. The data dictionary is therefore unavailable.

366

367 **Contributors**

368 AC, CH, RC, RM, LD, JO, and AF generated the research questions and analysis plan. CH, JK,
369 JK, MC, DA and The AvonCAP team were involved in data collection. AC, CH, RM, RC, LD,
370 and AF undertook data analysis. All authors (AC, CH, RC, RM, JK, DA, JK, MC, NM, JO, LD,
371 AF) were involved in the final manuscript preparation and its revisions before publication. The
372 data was verified by CH, DA, MC, JK and JK. AF provided oversight of the research.

373

374 **Declarations of Interest**

375 CH is Principal Investigator of the AvonCAP study which is an investigator-led University of
376 Bristol study funded by Pfizer and has previously received support from the NIHR in an
377 Academic Clinical Fellowship. JO and LD are Co-Investigators on the AvonCAP Study. AF is a
378 member of the Joint Committee on Vaccination and Immunization (JCVI) and, until December
379 2022 was chair of the World Health Organization European Technical Advisory Group of
380 Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as
381 Chief Investigator of this study, he leads another project investigating transmission of respiratory

382 bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no
383 relevant conflicts of interest to declare.

384

385 **Acknowledgements**

386 We thank Jennifer Nguyen, Joanna Southern, Bradford Gessner, John McLaughlin, Gillian
387 Ellsbury, Kaijie Pan, Luis Jodar, Elizabeth Begier, the UKHSA Vaccine Effectiveness Working
388 Group and the University of Bristol UNCOVER group for guidance in study design and data
389 analysis. We thank colleagues for their support with this study, including Rachel Davies, Paul
390 Savage, Emma Foose, Susan Christie, Mark Mummé, and Adam Taylor. We also thank the
391 research teams at North Bristol and University Hospitals of Bristol and Weston NHS Trusts for
392 making this study possible, including Helen Lewis-White, Rebecca Smith, Rajeka Lazarus, Mark
393 Lyttle, Kelly Turner, Jane Blazeby, Diana Benton, and David Wynick and all participants of the
394 many studies undertaken to find effective vaccines against SARS-CoV-2. LD and RC gratefully
395 acknowledge support from UKRI through the JUNIPER consortium (grant number
396 MR/V038613/1). LD is further supported through MRC (grant number MC/PC/19067), EPSRC
397 (EP/V051555/1).

398

399 **The AvonCAP Research Group:**

400 Anna Morley, Amelia Langdon, Anabella Turner, Anya Mattocks, Bethany Osborne, Charli
401 Grimes, Claire Mitchell, David Adegbite, Emma Bridgeman, Emma Scott, Fiona Perkins,
402 Francesca Bayley, Gabriella Ruffino, Gabriella Valentine, Grace Tilzey, James Campling,

403 Johanna Kellett Wright, Julia Brzezinska, Julie Cloake, Katarina Milutinovic, Kate Helliker,
404 Katie Maughan, Kazminder Fox, Konstantina Minou, Lana Ward, Leah Fleming, Leigh
405 Morrison, Lily Smart, Louise Wright, Lucy Grimwood, Maddalena Bellavia, Madeleine Clout,
406 Marianne Vasquez, Maria Garcia Gonzalez, Milo Jeenes-Flanagan, Natalie Chang, Niall Grace,
407 Nicola Manning, Oliver Griffiths, Pip Croxford, Peter Sequenza, Rajeka Lazarus, Rhian Walters,
408 Robin Marlow, Robyn Heath, Rupert Antico, Sandi Nammuni Arachchge, Seevakumar Suppiah,
409 Taslima Mona, Tawassal Riaz, Vicki Mackay, Zandile Maseko, Zoe Taylor, Zsolt Friedrich,
410 Zsuzsa Szasz-Benczur.

411

412


413 REFERENCES

- 414 1. Joint Committee on Vaccination and Immunisation (JCVI) statement on COVID-19
415 vaccinations in 2022: 21 February 2022. [https://www.gov.uk/government/publications/joint-](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022)
416 [committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022)
417 [committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022)
418 [21-february-2022](https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022).
- 419 2. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety,
420 immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given
421 as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third
422 dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. *Lancet*
423 *Infect Dis.* 2022;22:1131–41.
- 424 3. Kirsebom FCM, Andrews N, Stowe J, Groves N, Chand M, Ramsay M, et al. Effectiveness of
425 the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in
426 England. *Lancet Reg Health – Eur.* Elsevier; 2022;23.
- 427 4. Luring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical
428 severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and
429 alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ.* British
430 *Medical Journal Publishing Group;* 2022;376:e069761.
- 431 5. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9
432 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study
433 in Sweden. *Lancet Lond Engl.* 2022;399:814–23.
- 434 6. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of
435 BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and
436 severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ.* British Medical
437 *Journal Publishing Group;* 2021;374:n1943.
- 438 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of
439 COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in
440 England. *Nat Med.* 2022;28:831–7.
- 441 8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-
442 1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med.* 2022;28:1063–71.
- 443 9. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of
444 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination
445 and Delta Variant Predominance. *JAMA.* 2022;327:1032–41.
- 446 10. Lin D-Y, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, et al. Association of Primary and
447 Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19
448 Outcomes. *JAMA.* 2022;328:1415–26.

- 449 11. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-
450 Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency
451 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of
452 Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January
453 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:255–63.
- 454 12. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of
455 Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med.*
456 2022;386:340–50.
- 457 13. Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine.
458 [https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-](https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-originalomicron-booster-vaccine)
459 [originalomicron-booster-vaccine.](https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-originalomicron-booster-vaccine)
- 460 14. Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines.
461 [https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-](https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine)
462 [originalomicron-booster-vaccine.](https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine)
- 463 15. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent Omicron-
464 Containing Booster Vaccine against Covid-19. *N Engl J Med.* 2022;387:1279–91.
- 465 16. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, et al. Immunogenicity
466 of the BA.5 Bivalent mRNA Vaccine Boosters. *bioRxiv.* 2022;2022.10.24.513619.
- 467 17. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, et al. Antibody responses to
468 Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot. *bioRxiv.* 2022;2022.10.22.513349.
- 469 18. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. mRNA bivalent booster
470 enhances neutralization against BA.2.75.2 and BQ.1.1. *bioRxiv.* 2022;2022.10.31.514636.
- 471 19. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-
472 2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent
473 booster. *Nat Med.* 2022;1–1.
- 474 20. England Summary | Coronavirus (COVID-19) in the UK. <https://coronavirus.data.gov.uk>.
475 2023.
- 476 21. Lineages (raw) | COVID-19 Genomic Surveillance – Wellcome Sanger Institute.
477 [https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&line-](https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2)
478 [ages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C](https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2)
479 [0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2.](https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2)
- 480 22. Hyams C, Challen R, Begier E, Southern J, King J, Morley A, et al. Incidence of community
481 acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A
482 prospective cohort study. *Lancet Reg Health – Eur.* Elsevier; 2022;21.

- 483 23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
484 capture (REDCap)—A metadata-driven methodology and workflow process for providing
485 translational research informatics support. *J Biomed Inform.* 2009;42:377–81.
- 486 24. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2
487 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at
488 least 80 years: a test-negative, case-control study. *Lancet Infect Dis.* Elsevier; 2021;21:1539–48.
- 489 25. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3
490 September 2022. [https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-
491 2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-
492 programme-for-autumn-2022-update-15-august-2022](https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022).
- 493 26. Greenland S. Quantifying biases in causal models: classical confounding vs collider-
494 stratification bias. *Epidemiol Camb Mass.* 2003;14:300–6.
- 495 27. SARS-CoV-2 variants of concern and variants under investigation in England: Technical
496 briefing 50.
- 497 28. Wright DW, Harvey WT, Hughes J, Cox M, Peacock TP, Colquhoun R, et al. Tracking
498 SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer. *Virus Evol.*
499 2022;8:veac023.
- 500 29. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron
501 (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A
502 prospective cohort study in Bristol, United Kingdom. *Lancet Reg Health - Eur.* 2023;25:100556.
- 503 30. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
504 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron
505 (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet.*
506 2022;399:1303–12.
- 507 31. Cerqueira-Silva T, Oliveira V de A, Boaventura VS, Pescarini JM, Júnior JB, Machado TM,
508 et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and
509 CoronaVac vaccines: A population-based study. *Lancet Reg Health – Am.* Elsevier; 2022;6.
- 510 32. COVID-19 vaccine surveillance report: week 5.
511 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file
512 /1134076/vaccine-surveillance-report-week-5-2023.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1134076/vaccine-surveillance-report-week-5-2023.pdf).
- 513 33. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of
514 BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults
515 with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and
516 July 2022: A prospective test negative case–control study. *Lancet Reg Health - Eur.*
517 2023;25:100552.

518

A**B**